GlassScriptPhysician profile
Sonya J Chelliah
NPI 1811480411
$4,844.76
in general payments reported to CMS, 2019-2025
32 companies · $1,774 in 2025
The $1,774 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.20 · 2021: $26.40 · 2022: $552 · 2023: $871 · 2024: $1,597 · 2025: $1,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $791.06 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $519.35 | 2023-2025 | |
| Lilly USA, LLC | $502.79 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $453.43 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $369.68 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $253.81 | 2022-2025 | |
| Inspire Medical Systems, INC. | $175.83 | 2024-2025 | Inspire |
| Amgen INC. | $163.43 | 2022-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $151.46 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $136.17 | 2023-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $129.23 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $129.14 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $100.41 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.93 | 2023-2025 | Xifaxan, Trulance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.30 | 2024-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $79.74 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $74.10 | 2025 | Qelbree |
| Abbott Laboratories | $67.10 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Mylan Specialty L.P. | $61.10 | 2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.79 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $51.28 | 2023 | Rexulti |
| Corium, LLC | $40.87 | 2023 | Azstarys |
| Dexcom, INC. | $39.77 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $36.21 | 2024-2025 | Voquezna |
| Edwards Lifesciences Corporation | $29.76 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $27.44 | 2023-2024 | Gardasil 9, M-M-R II, Vaxneuvance |
| Impel Pharmaceuticals INC. | $27.31 | 2023 | Trudhesa |
| Paratek Pharmaceuticals, INC. | $24.10 | 2025 | Nuzyra |
| Actelion Pharmaceuticals US, INC. | $19.76 | 2025 | Uptravi, Opsumit |
| Welch Allyn | $13.41 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Chelliah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.